Clotting Time in Transfemoral PCI Linked to Bleeding Risk
WEDNESDAY, June 27, 2018 -- Higher maximal activated clotting time (ACT) is associated with a greater risk of major bleeding after transfemoral (TF) percutaneous coronary intervention (PCI) than after transradial (TR) PCI, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 27, 2018 Category: Pharmaceuticals Source Type: news

Corindus wins Japanese PMDA clearance for CorPath GRX platform
Corindus Vascular Robotics (OTC:CVRS) said today it won clearance from Japan’s Pharmaceutical and Medical Device Agency for its CorPath GRX robotic surgical device. The CorPath GRX vascular robotics platform is designed to assist cardiologists in performing percutaneous coronary interventions, including angioplasty and stent placement, Corindus said. “I look forward to offering CorPath GRX to my patients during PCI, especially in complex procedures where precision and procedural control are extremely valuable. We are pleased to be one of the first Asia-Pacific countries to adopt this new and innovative tec...
Source: Mass Device - June 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Regulatory/Compliance Robotics Vascular Corindus Vascular Robotics Source Type: news

Consistent CTO: Trial Finds Benefit of PCI for Total Occlusion Consistent CTO: Trial Finds Benefit of PCI for Total Occlusion
Percutaneous coronary intervention opened 90% of complex chronic total occlusions and offered quality-of-life benefits to a contemporary cohort of highly symptomatic patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 4, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Many Prescriptions for Newer, More Expensive Antiplatelet Agents Go Unfilled Many Prescriptions for Newer, More Expensive Antiplatelet Agents Go Unfilled
Prescriptions for the P2Y12 inhibitors prasugrel hydrochloride and ticagrelor hydrochloride after percutaneous coronary intervention (PCI) are outpacing those for clopidogrel, but many patients are not filling those prescriptions, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Reporting outcomes of PCI may not improve care
(Reuters Health) - Public reporting of outcomes for percutaneous coronary intervention (PCI) was supposed to improve quality, but some doctors say it hasn't delivered on the goal of enhancing patient care. (Source: Reuters: Health)
Source: Reuters: Health - May 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Doctors May Avoid Performing PCI Due to Public Reporting
WEDNESDAY, May 16, 2018 -- Current percutaneous coronary intervention (PCI) public reporting programs could have negative effects, with physicians avoiding PCI in high-risk patients, according to a study published online May 9 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 16, 2018 Category: Pharmaceuticals Source Type: news

How do public 'report cards' affect physicians' treatment decisions?
(Beth Israel Deaconess Medical Center) Researchers from the Smith Center for Outcomes Research in Cardiology at Beth Israel Deaconess Medical Center (BIDMC) provide a closer look at physicians' knowledge, attitudes and beliefs about public reporting on percutaneous coronary intervention (PCI). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 10, 2018 Category: International Medicine & Public Health Source Type: news

Zoll Medical leads debt round for TherOx
TherOx said today it completed a new round of debt financing led by Asahi Kasei (TYO:3407) subsidiary Zoll Medical for an undisclosed amount. Funds from the deal will be used to support the US market introduction and commercialization of the Irvine, Calif.-based company’s SuperSaturated Oxygen Therapy system designed to treat patients with acute myocardial infarction once the system wins FDA premarket approval. TherOx said that it also recently released results from a study of its SSO2 Therapy system which confirmed the safety and effectiveness of the device in the treatment of anterior acute myocardia...
Source: Mass Device - May 7, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Asahi Kasei Corp. TherOx Inc Zoll Medical Corp. Source Type: news

Timely Receipt of PCI in STEMI Up With Hospital Bypass Policy
TUESDAY, May 1, 2018 -- Adoption of policies allowing emergency medical services (EMS) to bypass non-percutaneous coronary intervention (PCI) capable hospitals for patients with ST-segment elevation myocardial infarction (STEMI) is associated with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news

SCAI updates consensus on length of stay for percutaneous coronary intervention
(Society for Cardiovascular Angiography and Interventions) Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary intervention (PCI) will allow for flexibility in length of stay while ensuring patient safety. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 25, 2018 Category: International Medicine & Public Health Source Type: news

Heavy US Burden of 30-Day Readmissions After PCI Heavy US Burden of 30-Day Readmissions After PCI
Almost 1 in 10 Americans undergoing percutaneous coronary intervention return with an unplanned readmission within 30 days, despite advances in the technology.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Abbot launches study comparing OCT to angiography in stent placement procedures
Abbott (NYSE:ABT) today announced the launch of new trial exploring long-term outcomes in patients who underwent stent implantation guided by optical coherence tomography as compared to angiography. The first patient in the trial was enrolled by Dr. Franco Fabbiocchi at Milan, Italy’s IRCCS Centro Cardiologico, the Abbot Park, Ill.-based company said. “Today, most of the world uses angiography for stent implantation using a two-dimensional view of the coronary artery to assess a complex three-dimensional structure. Physicians need new technology to help optimize percutaneous coronary intervention, and OCT ...
Source: Mass Device - April 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Imaging Abbott Source Type: news

Abbott launches study comparing OCT to angiography in stent placement procedures
Abbott (NYSE:ABT) today announced the launch of new trial exploring long-term outcomes in patients who underwent stent implantation guided by optical coherence tomography as compared to angiography. The first patient in the trial was enrolled by Dr. Franco Fabbiocchi at Milan, Italy’s IRCCS Centro Cardiologico, the Abbot Park, Ill.-based company said. “Today, most of the world uses angiography for stent implantation using a two-dimensional view of the coronary artery to assess a complex three-dimensional structure. Physicians need new technology to help optimize percutaneous coronary intervention, and OCT ...
Source: Mass Device - April 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Imaging Abbott Source Type: news

Better PCI Outcomes With Genotype-guided Antiplatelet Therapy Better PCI Outcomes With Genotype-guided Antiplatelet Therapy
The use of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention (PCI) is associated with better clinical outcomes, according to a new study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 10, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Abiomed Earns FDA Approval for Adding Optical Sensor to Impella CP Heart Pump
Abiomed, which had a busy 2017 and was among our Company of the Year finalists, reported today that it has received FDA premarket approval (PMA) for its Impella CP heart pump with SmartAssist, utilizing an optical sensor. The sensor is one component of the SmartAssist technology, which also includes a software update enabling informational displays of left ventricular pressure (LVP), end-diastolic pressure (EDP), and cardiac power output (CPO) data on the Impella Console, an Abiomed spokesperson told MD+DI. The Impella CP heart pump had already earned FDA approval for treating patients in cardiogenic shock as well as patie...
Source: MDDI - April 2, 2018 Category: Medical Devices Authors: Daphne Allen Tags: Cardiovascular Source Type: news

FDA clears robotic movement software from Corindus
The FDA granted 510(k) clearance to the first automated robotic movement software designed for Corindus Vascular Robotics (OTC:CVRS) CorPath GRX percutaneous coronary intervention platform, the company reported today. The Rotate on Retract feature allows the person operating the CorPath GRX to navigate to a targeted lesion by automatically turning the guidewire upon joystick retraction. The software also won CE Mark approval in the European Union earlier this year. Today, Dr. Nelson Bernado, the medical director of MedStar Heart Institute’s Peripheral Vascular Laboratory, is slated to perform a robotic-assited p...
Source: Mass Device - March 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Regulatory/Compliance Robotics Software / IT Vascular Corindus Vascular Robotics Source Type: news

ACC, Saudi Arabian Cardiac Interventional Society partner on registries
(American College of Cardiology) The American College of Cardiology and the Saudi Arabian Cardiac Interventional Society have partnered to implement the National Cardiovascular Data Registry's (NCDR) CathPCI Registry in hospitals across Saudi Arabia. The CathPCI Registry assesses the characteristics, treatments and outcomes of heart disease patients who receive diagnostic catheterization as well as percutaneous coronary intervention procedures. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 27, 2018 Category: International Medicine & Public Health Source Type: news

Abiomed wins expanded Impella FDA nod for elective, urgent high-risk PCI
Abiomed (NSDQ:ABMD) said today it won expanded FDA premarket approval for its Impella 2.5 and Impella CP heart pumps, now cleared for use during elective and urgent high risk percutaneous coronary intervention procedures. With the expansion, the Impella heart pump is cleared for use with patients with severe coronary artery disease, complex anatomy and a number of co-morbidities with or without depressed ejection fractions, the Danvers, Mass.-based company said. “This expanded FDA approval with moderately reduced ejection fraction validates our real-world experience using hemodynamic support in patients turned d...
Source: Mass Device - February 14, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiovascular Catheters Food & Drug Administration (FDA) Regulatory/Compliance Abiomed Source Type: news

Shorter time between first medical contact to PCI in heart patients linked to saving lives
(European Society of Cardiology) Heart experts are calling for immediate action following new research in the European Heart Journal that shows every minute counts for patients who suffer the most severe type of heart attack. The study shows numbers of deaths rise steadily and rapidly the longer the time between patients' first contact with a medical professional and when they are treated in hospital with percutaneous coronary intervention (PCI) to insert a balloon catheter to widen blocked arteries and restore blood flow to the heart. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 13, 2018 Category: International Medicine & Public Health Source Type: news

Doctors may be ordering too many coronary interventions
Physicians may be ordering too many percutaneous coronary intervention procedures...Read more on AuntMinnie.comRelated Reading: FFR-CT algorithm guides management of revascularization Use criteria cut unnecessary heart interventions NIH study ties soft plaque on CT to cardiac risk factors (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 16, 2018 Category: Radiology Source Type: news

Percutaneous coronary intervention is a well-justified option also in severe coronary artery disease
(University of Eastern Finland) The treatment of left main coronary artery disease by percutaneous coronary intervention is associated with a smaller risk of severe cardiovascular events than coronary artery bypass grafting in the weeks following surgery. A meta-analysis of several trials and nearly 5,000 patients revealed no differences in mortality between the two treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2017 Category: International Medicine & Public Health Source Type: news

When to Stent in Stable CAD? That Is (Still) the Question When to Stent in Stable CAD? That Is (Still) the Question
Drs Harrington, Maron, and Patel discuss the ORBITA trial, which compared coronary stenting with sham percutaneous coronary intervention for angina relief. Why did ORBITA cause so much buzz?theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 22, 2017 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Perioperative Aspirin Might Benefit Patients with Prior PCI
Perioperative aspirin seems beneficial for high-risk patients undergoing noncardiac surgery who've previously undergone percutaneous coronary intervention (PCI), according to a subanalysis from the POISE... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 14, 2017 Category: Primary Care Source Type: news

Aspirin can prevent heart attacks after noncardiac surgery in patients with prior PCI
(University of Alberta Faculty of Medicine& Dentistry) A Canadian-led study has found that perioperative aspirin can prevent heart-related complications after major noncardiac surgery in patients with previous percutaneous coronary intervention (PCI) such as an angioplasty or stent. The study found that for every 1,000 patients with PCI, giving them aspirin at the time of noncardiac surgery would prevent 59 heart attacks and cause eight major bleeding events. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 14, 2017 Category: International Medicine & Public Health Source Type: news

Study: PCI Appears No Better Than Sham Procedure in Patients with Stable Angina (FREE)
By Kelly Young Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS Percutaneous coronary intervention (PCI) didn't improve exercise time relative to a sham procedure in patients with stable angina and severe coronary stenosis. Findings from the ORBITA study were published in the Lancet and presented at the … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 3, 2017 Category: Primary Care Source Type: news

Analysis Shows Better Health Outcomes and Cost Effectiveness for Coronary Intervention Using Abbott's Fractional Flow Reserve (FFR) Diagnostic in Patients with Stable Coronary Artery Disease
After three years, patients who underwent FFR-guided percutaneous coronary intervention (PCI) in combination with medical therapy had significantly fewer major adverse cardiac events compared to patients who received medical therapy alone (Source: Abbott.com)
Source: Abbott.com - November 2, 2017 Category: Pharmaceuticals Source Type: news

Should patients with cardiogenic shock receive culprit lesion only PCI or multivessel PCI?
(Cardiovascular Research Foundation) Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found that an initial strategy of culprit lesion only percutaneous coronary intervention (PCI) reduces the composite of 30-day mortality and/or severe renal failure in patients with multivessel disease and cardiogenic shock complicating acute myocardial infarction. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 31, 2017 Category: International Medicine & Public Health Source Type: news

SCAI launches educational initiative as nation shifts to value-based healthcare
(Society for Cardiovascular Angiography and Interventions) The Society for Cardiovascular Angiography and Interventions announced today the launch of TRAnsition for VALUE, a multi-faceted educational initiative supported by Medtronic, to inform cardiologists, hospital administrators, and cath lab staff about the benefits of expanding the adoption of transradial (wrist access) percutaneous coronary intervention (PCI) in the US. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 30, 2017 Category: International Medicine & Public Health Source Type: news

FDA clears expansion of CeloNova ’s nano-coated coronary stent trial
CeloNova Biosciences said today that the FDA approved an expansion of the on-going clinical trial for its Cobra PzF nano-coated coronary stent with 14-day dual antiplatelet therapy in complex patients, like people who are at a high risk of bleeding. The company touted its Cobra Reduce trial as the first randomized control trial to study 14-day DAPT following percutaneous coronary intervention. Get the full story at our sister site, Drug Delivery Business News. The post FDA clears expansion of CeloNova’s nano-coated coronary stent trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 26, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Stents Vascular CeloNova BioSciences Source Type: news

Registry data examines oral anticoagulant use in women, adverse events after PCI discharge
(American College of Cardiology) Data from the American College of Cardiology's National Cardiovascular Data Registry was the source of several published studies in recent months, including a study on predicting 30-day readmission rates for patients undergoing percutaneous coronary intervention and a study that found women were less likely to use oral anticoagulants to treat atrial fibrillation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 5, 2017 Category: International Medicine & Public Health Source Type: news

Andreas Roland Gruentzig, the Man Andreas Roland Gruentzig, the Man
A fascinating profile of Andreas Gruentzig, the renowned cardiologist who first developed balloon angioplasty, and is considered the father of modern-day percutaneous coronary intervention.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

MassDevice.com +5 | The top 5 medtech stories for September 20, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. The 10 largest medical device companies in the world Mergers & acquisitions continue to change the medical device landscape, as reflected in Medical Design & Outsourcing’s new Big 100 list. We pulled financial reg...
Source: Mass Device - September 20, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Reva Medical ’s Fantom bioresorbable, drug-eluting vascular scaffold succeeds at 6 months
As some companies have worked to improve drug-eluting stents by making them bioresorbable, some voices in the coronary intervention space have expressed concern over the rates of late stent thrombosis and repeat percutaneous coronary intervention seen with the devices. In a study published in the September issue of JACC: Cardiovascular Intervention, Reva Medical‘s (ASX:RVA) Fantom coronary bioresorbable vascular scaffold succeeded after six months. The device was designed to address challenges like strut size and expansion capacity, the researchers wrote. Get the full story at our sister site, Drug Delivery...
Source: Mass Device - September 20, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Drug-Eluting Stents Pharmaceuticals Wall Street Beat Abbott Reva Medical Inc. Source Type: news

Study examines use of systolic blood pressure at time of primary percutaneous coronary intervention
(Society for Cardiovascular Angiography and Interventions) Researchers have led a retrospective single-center study examining simple hemodynamic parameters obtained at the time of cardiac catheterization to predict in-hospital mortality following ST-elevation myocardial infarction (STEMI). Current 30-day mortality rates for patients with STEMI range from 2.5% to 10%, and 10.5%-24% of those patients require mechanical hemodynamic support. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 11, 2017 Category: International Medicine & Public Health Source Type: news

BLS Crews in Paris Detect Atypical STEMI via 12-Lead ECG
By Jonathan Gonzva, MD; Laure Alhanati, MD; Stéphane Dubourdieu, MD; Daniel Jost, MD; Hugues Lefort, MD; Benoît Frattini, MD & Jean-Pierre Tourtier, MD A 61-year-old man calls the Paris Fire Brigade dispatch center with a complaint of dental pain. He reports feeling pain in the jaw for the past 35 minutes, which he says now extends to the armpits. He also reports that he experienced the same feeling the day before. The patient's age and hyperlipidemia were his only cardiovascular risk factors with atorvastatine and budesonide as the usual treatments. The physician stationed at the dispatch cen...
Source: JEMS Patient Care - September 7, 2017 Category: Emergency Medicine Tags: International Cardiac & Resuscitation Columns Patient Care Source Type: news

Rethinking dual antiplatelet guidelines in acute coronary syndrome? (CHANGE-DAPT)
(European Society of Cardiology) New research presented at ESC Congress today1 suggests that for acute coronary syndrome (ACS) patients who require percutaneous coronary intervention (PCI), treatment according to contemporary guidelines for dual anti-platelet therapy (DAPT) could be less preferable than sticking to older guidelines. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 29, 2017 Category: International Medicine & Public Health Source Type: news

Angioplasty outcomes almost equal among hospitals
Patients who undergo percutaneous coronary intervention have similar outcomes at different hospitals, researchers said. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 8, 2017 Category: Consumer Health News Source Type: news

Angioplasty Outcomes Almost Equal Among Hospitals
MONDAY, Aug. 7, 2017 -- Patients who have an artery-opening procedure called percutaneous coronary intervention (PCI) have similar outcomes whether they're treated at so-called safety-net or non-safety-net hospitals, researchers say. Safety-net... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 7, 2017 Category: General Medicine Source Type: news

Blacks and Whites Have Similar Outcomes After PCI Blacks and Whites Have Similar Outcomes After PCI
A study designed to look for differing outcomes when black and white U.S. veterans undergo percutaneous coronary intervention (PCI) instead found no differences once confounding factors were taken into account.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - July 25, 2017 Category: Intensive Care Tags: Family Medicine/Primary Care News Source Type: news

Roxwood Medical Announces Agreement with Abbott for Distribution of Products in U.S.
REDWOOD CITY, Calif., July 25, 2017 -- (Healthcare Sales & Marketing Network) -- Roxwood Medical Inc., a leading provider of advanced cardiovascular specialty catheters, today announced it has entered into an exclusive agreement with Abbott for distributi... Devices, Interventional, Cardiology, Distribution Roxwood Medical, Abbott, CenterCross, Percutaneous coronary intervention (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 25, 2017 Category: Pharmaceuticals Source Type: news

Bayer ’s Xarelto in Combination with Single Antiplatelet Therapy Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation requiring oral Anticoagulation and undergoing Percutaneous Coronary Intervention with Stent Placement (for specialized target groups only)
Positive CHMP Opinion is based on data from the Phase IIIb PIONEER AF-PCI study, which demonstrated significantly reduced rates of clinically significant bleeding with Xarelto compared with VKA in patients with non-valvular atrial fibrillation (AF) who require oral anticoagulation and are also receiving antiplatelet therapy after percutaneous coronary intervention (PCI) with stent placement (1) / PIONEER AF-PCI is the first and currently only randomised clinical trial of a non-vitamin K antagonist oral anticoagulant (NOAC) in this patient population / Final decision of European Commission expected by the end of this year (...
Source: Bayer Company News - July 21, 2017 Category: Pharmaceuticals Source Type: news

21.07.17: Not intended for U.S. and UK Media
Bayer's Xarelto in Combination with Single Antiplatelet Therapy Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation requiring oral Anticoagulation and undergoing Percutaneous Coronary Intervention with Stent PlacementPositive CHMP Opinion is based on data from the Phase IIIb PIONEER AF-PCI study, which demonstrated significantly reduced rates of clinically significant bleeding with Xarelto compared with VKA in patients with non-valvular atrial fibrillation (AF) who require oral anticoagulation and are also receiving antiplatelet therapy after percutaneous coronary intervention (PCI) with stent...
Source: Bayer IR Newsfeed: Events - July 20, 2017 Category: Pharmaceuticals Source Type: news

Heart vessel-clearing procedure can benefit some at age 90 and older
People in their nineties and older represent a tiny but growing fraction of patients who undergo a procedure called percutaneous coronary intervention (PCI) to clear blocked blood vessels in the heart, new research shows. (Source: Reuters: Health)
Source: Reuters: Health - July 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Prolonged DAPT After PCI: Risk Score Helps Identify Those Most Likely to Be Harmed (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD The DAPT (dual antiplatelet therapy) score helps identify patients for whom prolonged treatment after percutaneous coronary intervention would be harmful, suggests an analysis in the Annals of Internal Medicine. Researchers retrospectively applied … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 13, 2017 Category: Primary Care Source Type: news

No difference in rate of adverse cardiovascular events when comparing anticoagulants
In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 17, 2017 Category: Science Source Type: news

Large multicenter study shows high success rate for robotic PCI procedures
Results from the PRECISION trial (Efficacy and Safety Outcomes of Radial- vs Femoral-Access Robotic Percutaneous Coronary Intervention: Final Results of the Multicenter PRECISION Registry) were presented today as a late-breaking clinical trial. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 12, 2017 Category: Science Source Type: news

Blood Vessel-Clearing Procedure Riskier on Weekends: Study
THURSDAY, May 11, 2017 -- Although you often don't have a choice of when you get the heart procedure called percutaneous coronary intervention (PCI), new research suggests that having it done over the weekend may be more risky. The study reported... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 11, 2017 Category: General Medicine Source Type: news

Abiomed dips on missed Q4 earnings, despite sales beat
Share prices for Abiomed (NSDQ:ABMD) dipped today after the company reported fiscal 4th-quarter earnings that missed expectations, despite a top-line gain of nearly 33%. The Danvers, Mass.-based heart pump maker posted profits of $14.9 million, or 33¢ per share, on sales of $124.7 million for the 3 months ended March 31, for a bottom-line increase of 35.5% on sales growth of 32.7% compared with Q4 2016. But analysts on Wall Street were looking for earnings per share of 35¢; Abiomed topped the consensus Street estimate for sales by more than $2 million. Full-year profits were $52.1 million, or $1.17 per share...
Source: Mass Device - May 4, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Assist Devices MassDevice Earnings Roundup Wall Street Beat Abiomed Source Type: news

Cardiovascular Systems launches combined Diamondback 360, DES trial
Cardiovascular Systems (NSDQ:CSII) said today it enrolled the 1st patient in the Eclipse clinical trial of its Diamondback 360 coronary orbital atherectomy system. The St. Paul, Minn.-based company is looking to enroll 2,000 patients in the trial which aims to explore the use of the Diamondback 360 device for treating patients with severely calcified coronary lesions prior to drug-eluting stent placement. A control group will consist of patients treated with conventional angioplasty, including specialty balloons, prior to DES placement, the comapny said. The trial’s primary endpoint will be post-procedural minim...
Source: Mass Device - March 29, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Catheters Clinical Trials Cardiovascular Systems Inc. Source Type: news

Teleflex (TFX) Announces 510(k) Clearance and U.S. Launch of Spectre(TM) Guidewire
WAYNE, Pa.--(Healthcare Sales & Marketing Network)--Teleflex Incorporated (TFX), a leading global provider of medical technologies for critical care and surgery, has announced 510(k) clearance by the Food and Drug Administration and U.S. commercial launch ... Devices, Interventional, Cardiology, FDA, Product Launch Teleflex, Spectre Guidewire, percutaneous coronary intervention (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 14, 2017 Category: Pharmaceuticals Source Type: news